Results 241 to 250 of about 3,446,938 (405)

The pathogenesis of severe asthma: A consensus report from the workshop on pathogenesis

open access: bronze, 1987
Jeffrey M. Drazen   +7 more
openalex   +1 more source

Analysis of Differentially Expressed Proteins Involved in Shrimp and Crab Allergies

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Using proteomics techniques, we identified 90 differentially expressed proteins in children with shrimp and crab allergies compared to normal controls, with 82 upregulated and 8 downregulated proteins. Validation of MRC2 upregulation by ELISA in allergic patients highlights the potential role of this protein in the allergic response.
Ruhong Tan   +4 more
wiley   +1 more source

Neutrophilic Inflammation in Severe Persistent Asthma [PDF]

open access: green, 1999
Anon Jatakanon   +5 more
openalex   +1 more source

Examining the Impact of Diet‐and‐Exercise‐Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Obesity significantly influences drug pharmacokinetics (PK), which challenges optimal dosing. This study examines the effects of diet‐and‐exercise‐induced weight loss on key drug‐metabolizing enzymes and gastric emptying in patients with obesity, who frequently require medications for comorbidities.
Shuhan Liu   +8 more
wiley   +1 more source

Psychological intervention in severe asthma: from theory to practice. [PDF]

open access: yesEur Clin Respir J
Fernández Aracil C   +5 more
europepmc   +1 more source

Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study [PDF]

open access: bronze, 1999
Catherine Neukirch   +5 more
openalex   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Home - About - Disclaimer - Privacy